In turn, synthetic ERα ligands (e.g., fulvestrant and tamoxifen) and molecules that do not bind the receptor (e.g., chloroquine, emetine and carfilzomib) alter intracellular ERα levels and inhibit BC cell proliferation [3,12]. Here, ESR1 is linked to breast cancer.